Este archivo ha sido creado el 19.01.2025 por Matilde Durán Lobato GENERAL INFORMATION ------------------ 1. Dataset title: Dataset from Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids. Journal of Nanoparticle Research, 2015, vol. 17, article 61.(v.0) 2. Authorship: [ Obligatorio | Ponga la información de todos los autores siguiendo el suiguiente formato. Repita el esquema para cada autor.] Matilde Durán-Lobato Universidad de Sevilla ORCID: 0000-0001-5534-6955 Email: mduran@us.es Lucía Martín-Banderas Universidad de Sevilla ORCID: 0000-0003-1447-6125 Email: luciamartin@us.es Lídia M. D. Gonçalves Universidade de Lisboa ORCID: 0000-0002-6799-2740 Email: lgoncalves@ff.ulisboa.pt Mercedes Fernández-Arévalo Universidad de Sevilla ORCID: 0000-0002-4283-3356 Email: mfarevalo@us.es António J. Almeida Universidade de Lisboa ORCID: 0000-0002-7807-4726 Email: aalmeida@ff.ulisboa.pt DESCRIPTION ---------- 1. Dataset language: English 2. Abstract: This dataset corresponds to the article “Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids, published in the Journal of Nanoparticle Research”. The dataset includes experimental data from the formulation, characterization, and evaluation of CB13-loaded PLGA and lipid nanoparticles (NPs), including changes in zeta potential, release studies, cytotoxicity assays (Caco-2 cells) and cellular uptake assays. 3. Keywords: Cannabinoids; Oral administration; Neuropathic pain; Lipid nanoparticles; PLGA Nanoparticles; Nanomedicine Cannabinoides; Administración oral; Dolor neuropático; Nanopartículas lipídicas; Nanopartículas de PLGA; Nanomedicina 4. Date of data collection (fecha única o rango de fechas): 01.05.2013 – 31.12.2014 5. Publication Date: 30-01-2015 6. Grant information: [ Obligatorio si aplicable | Financiación recibida. Repita el esquema para cada organismo financiador.] Grant Agency: IV Plan Propio de la Universidad de Sevilla Grant Number: Contrato de Acceso L. M-B, Beca PIF y Contrato Puente Postdoctoral M. D-L Grant Agency: Junta de Andalucía Grant Number: Project P09-CTS-5029 Grant Agency: Fundação para a Ciência e a Tecnologia (FCT) Grant Number: PTDC/EBB-BIO/101237/2008 and PEst-OE/SAU/UI4013/2011 7. Geographical location/s of data collection: Facultad de Farmacia. Prof García González, 2, 41012 Sevilla, Andalucia, España Campus Reina Mercedes Coordinates: 37°21′39″N 5°59′18″O / 37.36094167, -5.98836111 ACCESS INFORMATION ------------------------ 1. Creative Commons License of the dataset: CC_BY 2. Dataset DOI: 3. Related publication: Durán-Lobato, M., Martín-Banderas, L., Gonçalves, L.M.D., Fernández-Arévalo, M., Almeida, A.J. (2015). Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids. Journal of Nanoparticle Research, 17:61. DOI: 10.1007/s11051-015-2875-y. 4. Link to related datasets: VERSIONING AND PROVENANCE --------------- 1. Last modification date: 19-01-2025 2. Were data derived from another source?: NO 3. Additional related data not included in this dataset: METHODOLOGICAL INFORMATION ----------------------- 1. Description of the methods used to collect and generate the data: The dataset includes experimental data from the synthesis, characterization, and biological evaluation of CB13-loaded PLGA and lipid nanoparticles (LNPs). Nanoparticles were prepared using nanoprecipitation and solvent evaporation methods. Surface modification with chitosan and PEG was performed to enhance mucoadhesion and oral bioavailability. Characterization data include particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency, and drug release profiles. Drug release was evaluated in phosphate buffer saline (PBS) at pH 7.4 with 0.1% Tween® 80 under sink conditions. Drug encapsulation and release were quantified using reverse-phase high-performance liquid chromatography (RP-HPLC). Biological evaluations included cytotoxicity assays on Caco-2 cells using the MTT test, hemocompatibility studies (hemolysis and platelet activation), and cellular uptake studies using fluorescently labeled nanoparticles. Cellular uptake was assessed in Caco-2 cells by flow cytometry and confocal microscopy to quantify and visualize nanoparticle internalization. All experiments were conducted in triplicate, and results are expressed as mean ± standard deviation. 2. Data processing methods: HPLC data were analyzed using Hitachi LaChrom® software for drug quantification and release profiles. Flow cytometry data for cellular uptake were analyzed using Cytomics FC 500 MPL software. Statistical analyses, including ANOVA and Student’s t-tests, were performed with SPSS software, with a significance level set at p < 0.05. 3. Software or instruments needed to interpret the data: N/A 4. Information about instruments, calibration and standards: Nanoparticle Synthesis: PLGA NPs: Prepared using nanoprecipitation with a syringe pump (Harvard Apparatus, USA) and magnetic stirring. Lipid NPs: Produced using solvent evaporation with a Branson Sonifier 250 (Danbury, USA) and a Silverson High-Speed Mixer L5 M (Silverson Machines, UK). Physicochemical Characterization: Size and Zeta Potential: Measured using a Malvern Zetasizer Nano ZS (Malvern Instruments, UK), calibrated with polystyrene standards. Morphology: Examined by transmission electron microscopy (TEM) using a Philips CM-10 microscope (Netherlands). Drug Encapsulation and Release: Quantified by reverse-phase HPLC (Hitachi LaChrom® D-7000 system) equipped with a Waters Spherisorb ODS2 column. Calibration curves were constructed with known concentrations of CB13 to ensure accuracy and precision. Biological Assays: Cytotoxicity: Caco-2 cells were exposed to various concentrations of nanoparticles for 24 and 48 hours. MTT assay results were measured using a Tecan Infinite 200 microplate reader. Hemocompatibility: Hemolysis and platelet activation assays were performed using validated spectrophotometric methods. Cellular Uptake: Fluorescently labeled nanoparticles were incubated with Caco-2 cells for 4 hours. Internalization was quantified using a Cytomics FC 500 MPL flow cytometer (Beckman Coulter, USA) and visualized via confocal laser scanning microscopy (CLSM) using a Zeiss LSM 510 microscope (Germany). 5. Environmental or experimental conditions: N/A 6. Quality-assurance procedures performed on the data: [Opcional] FILE OVERVIEW ---------------------- [Se han de mencionar todos los archivos incluidos en el conjunto de datos, con el nombre y la extensión (.csv, .pdf, etc.) de cada archivo. Incluya la estructura de directorios]. 1. Explain the file naming conversion, si es aplicable: A single Excel file with each sheet collecting the data corresponding to a figure or table: -Figure 3: Data corresponding to manuscript Figure 3 on zeta potential values of the different formulations assayed. -Figure 5: Data corresponding to manuscript Figure 5 on the release profile of the different formulations assayed. -Figure 7: Data corresponding to manuscript Figure 7 on the cytotoxic effect on Caco-2 cells of different types of NPs assayed. -Figure 8: Data corresponding to manuscript Figure 8 on cell uptake of plain, PEG-coated and chitosan coated LNPs and PLGA NPs. 2. File list: File name: Dataset from Comparative study of chitosan- and PEG-coated lipid and polymeric nanoparticles as oral delivery systems for cannabinoids Description: A single Excel file with each sheet collecting the data corresponding to a figure or table: -Figure 3: Data corresponding to manuscript Figure 3 on zeta potential values of the different formulations assayed. -Figure 5: Data corresponding to manuscript Figure 5 on the release profile of the different formulations assayed. -Figure 7: Data corresponding to manuscript Figure 7 on the cytotoxic effect on Caco-2 cells of different types of NPs assayed. -Figure 8: Data corresponding to manuscript Figure 8 on cell uptake of plain, PEG-coated and chitosan coated LNPs and PLGA NPs. 3. Relationship between files: [ Obligatorio si es aplicable | Relación entre los archivos] 4. File format: Excel 5. If the dataset includes multiple files, specify the directory structure and relationships between the files: [ Obligatorio si es aplicable | Si el conjunto de datos incluye varios archivos, indique la estructura de directorios y las relaciones entre los archivos] SPECIFIC INFORMATION FOR TABULAR DATA ------------------------------------------- [Este apartado se debe repetir para cada archivo de datos que requiera la explicación de variables (habitualmente datos tabulados). Se describirán todas las variables, incluyendo las unidades de medida.] 1. Name file: [Opcional | Nombre del archivo] 2. Number of rows and columns: [Opcional |Número de filas y columnas] 3. Variables list: [Opcional | Repita la estructura para cada variable.] Variable name: Description: Units of measure or value labels | Unidades de medida o etiquetas de valor: 4. Codes or symbols for missing data: [Opcional | Repita la estructura para cada código o símbolo que faltan] Code or symbol: Definition: 5. Special formats or abbreviations used: [Opcional |Formatos especiales o abreviaturas utilizadas] MORE INFORMATION -------------- [Include any other information about the dataset that is not reflected in this template and that you consider relevant. Incluya cualquier otra información sobre el conjunto de datos que no haya quedado reflejada en esta plantilla y que considere relevante]